Increased plasma aldosterone during atrial fibrillation declines following cardioversion

Cardiology

Volumn 118, Issue 4, 2011, Pages 239-244

  Soeby Land, C ^a   Dixen, U ^b   Therkelsen, S K ^c   Kjaer, A ^d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aldosterone; Atrial fibrillation; Cardioversion; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINUS RHYTHM;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 79959831752     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000328462     Document Type: Article

References (27)

1. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB: Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666-672. (Pubitemid 40417013)
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952. (Pubitemid 28446646)
3. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L: Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32: 197-204. (Pubitemid 28351062)
4. Schotten U, Greiser M, Benke D, Buerkel K, Ehrenteidt B, Stellbrink C, Vazquez-Jimenez JF, Schoendube F, Hanrath P, Allessie M: Atrial fibrillation-induced atrial contractile dysfunction: A tachycardiomyopathy of a different sort. Cardiovasc Res 2002; 53: 192-201. (Pubitemid 34020780)
5. Allessie MA: Atrial electrophysiologic remodeling: Another vicious circle? J Cardiovasc Electrophysiol 1998; 9: 1378-1393. (Pubitemid 28565136)
6. Fenelon G, Wijns W, Andries E, Brugada P: Tachycardiomyopathy: Mechanisms and clinical implications. Pacing Clin Electrophysiol 1996; 19: 95-106. (Pubitemid 26033209)
7. Allessie M, Ausma J, Schotten U: Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246. (Pubitemid 34327903)
8. Jorde UP: Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: Choice of agents and clinical impact. Cardiol Rev 2006; 14: 81-87. (Pubitemid 44378512)
9. Swedberg K, Kjekshus J: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988; 62: 60A-66A.
10. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
12. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321 (erratum published in (Pubitemid 36384098)
13. N Engl J Med 2003; 348: 2271).
14. Therkelsen SK, Groenning BA, Svendsen JH, Jensen GB: Atrial and ventricular volume and function evaluated by magnetic resonance imaging in patients with persistent atrial fibrillation before and after cardioversion. Am J Cardiol 2006; 97: 1213-1219.
15. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU: Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88: 906-909. (Pubitemid 32995932)
16. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931. (Pubitemid 36736634)
17. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380. (Pubitemid 29362407)
18. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719. (Pubitemid 40282586)
19. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN, Val-HeFT Investigators: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557. (Pubitemid 40585420)
20. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336. (Pubitemid 34778957)
21. Madrid AH, Peng J, Zamora J, Marin I, Bernal E, Escobar C, Munos-Tinoco C, Rebollo JM, Moro C: The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004; 27: 1405-1410. (Pubitemid 39463659)
22. Tuinenburg AE, van Veldhuisen DJ, Boomsma F, van den Berg MP, de Kam PJ, Crijns HJ: Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol 1998; 81: 1207-1210. (Pubitemid 28226132)
23. Therkelsen SK, Groenning BA, Kjaer A, Svendsen JH, Jensen GB: ANP and BNP in atrial fibrillation before and after cardioversion -and their relationship to cardiac volume and function. Int J Cardiol 2007; 127: 396-399. (Pubitemid 351885074)
24. Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, Jensen GB: Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 2006; 108: 35-39.
25. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-34. (Pubitemid 27374737)
26. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.
27. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr.: Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1999;1:7-21.